Revenue
5Y CAGR +24.2%10Y CAGR +18.0%No quarters filed for this figure.
Form 4 transactions by trade date, as filed; latest on file 2026-11-12.
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Bar = where today’s multiple sits in ICLR’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).
No quarters filed for this figure.
No quarters filed for this figure.
No quarters filed for this figure.
FY25: operating cash flow $1B, capex −$174.2M
No quarters filed for this figure.
No quarters filed for this figure.
No quarters filed for this figure.
ICON plc is a clinical research organisation that provides outsourced drug and device development services to pharmaceutical, biotechnology, medical device, and public health customers. The company supports clinical development across the full product lifecycle, including study design, trial management, data solutions, site and patient access, laboratory services, and commercialization support. ICON plc also offers consulting and advisory capabilities, decentralized and hybrid trial services, real-world intelligence, and therapeutic expertise across areas such as oncology, cardiology, infectious disease, immunology, and central nervous system disorders. Its work is used to help clients run clinical programs more efficiently and bring medical treatments through development and approval pathways. Headquartered in Dublin, Ireland, ICON plc operates through a broad international network and serves organizations in multiple global markets.
Dublin, Ireland·40,200 employees·Diagnostics & Research·iconplc.com·As of Oct 28, 2026
3 of the 193 ETFs ChartRow carries live hold ICLR. Their positions, by the weight each fund filed in its latest SEC N-PORT report (Jul 26 to Aug 26).
| Fund | Name | Filed weight |
|---|---|---|
| ONEQ | Fidelity Nasdaq Composite Index ETF | 0.0% |
| ESGV | Vanguard ESG U.S. Stock ETF | 0.0% |
| VT | Vanguard Total World Stock ETF | 0.0% |
| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +12.61% | -1.13% |
| JNJ | Johnson & Johnson | +9.05% | -1.36% |
| ABBV | AbbVie Inc. | +2.59% | -0.59% |
| MRK | Merck & Co. Inc. | -1.77% | -0.75% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | -2.93% | -5.42% |
| NVS | Novartis AG | +5.65% | -0.67% |
| TMO | Thermo Fisher Scientific Inc. | -0.47% | -0.66% |
| AMGN | Amgen Inc. | +5.88% | -0.95% |